CoChat

Cellular assembly and functional resilience of the mammalian RNA exosome

Open access

The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index; none of the 74 sources its claims cite is checked for support yet.

Abstract

Most eukaryotic proteins assemble into multisubunit complexes that coordinate essential cellular functions, yet the principles governing their assembly and proteostatic control remain largely undefined. Here, we systematically dissect the cellular assembly and functional organization of the RNA exosome, an essential ribonucleolytic complex, using an inducible dual-guide CRISPR/Cas9 system in mouse embryonic stem cells. We reveal a sequential assembly pathway where Exosc2, Exosc4, and Exosc7 initiate complex formation, facilitating the incorporation of barrel and cap subunits in a defined hierarchy. Unlike other structural subunits, the terminally incorporated cap subunit Exosc1 is dispensable for cell viability, revealing a modular, functionally resilient architecture. We demonstrate that orphan subunits are selectively degraded via the ubiquitin-proteasome system, enforcing stringent quality control over RNA exosome biogenesis. These findings define an assembly logic of of the mammalian exosome and uncover previously unrecognized plasticity in the composition and function of this essential ribonucleolytic complex.

Overview

CoChat Summary

TL;DR

Using inducible dual-guide CRISPR/Cas9 and acute degron depletion in mouse embryonic stem cells, this study defines a stepwise cellular assembly pathway for the mammalian RNA exosome and shows that orphan subunits are degraded by the ubiquitin-proteasome system. It further finds that the terminal cap subunit Exosc1 is largely dispensable for RNA exosome function and mESC viability.

Key findings

  • RNA exosome core assembly is ordered: Exosc2, Exosc4, and Exosc7 form an initiating heterotrimer, followed by Exosc6, Exosc8, Exosc9, Exosc5, Exosc3, and finally Exosc1. Depletion of Exosc2/4/7 co-destabilized all core components, whereas Exosc1 depletion affected no other core subunit. Orphan Exosc4, Exosc5, Exosc7, and Exosc9 were stabilized by Epoxomicin or TAK-243 after Exosc2 depletion, implicating ubiquitin-proteasome degradation.
  • Most core subunits are required for proliferation, but Exosc1 is largely dispensable: after 7 days of Cas9 induction, Exosc1-depleted cells dropped only to ~50%, versus <10% remaining for other core components. Exosc1-KO mESCs were viable with moderate growth defects, rescued by V5-tagged Exosc1. Exosc1 depletion caused weaker PROMPT stabilization and rRNA processing defects; Exosc2 or Exosc6 depletion upregulated cleaved PARP and cleaved Caspase3, but Exosc1 depletion did not.
  • Catalytic subunit dependencies differ: Dis3L and Exosc10 undergo orphan decay, while Dis3 remains stable except upon direct depletion. Exosc10 stability depends on a fully assembled core including Exosc1; Dis3L depends on Exosc5 and Exosc3 but not Exosc1.
  • Assembly intermediates are detectable in wild-type cells: SEC and IP-MS recovered distinct subcomplexes, and inducible Exosc7-3xFLAG enriched Exosc2/4/7/6/8 at 60 min, then Exosc9/5/3 at 75 min, with all core subunits enriched by 90 min. In Exosc1-KO proteomes, among 5877 detected proteins, only 15 were down and eight upregulated; Exosc10 was among the downregulated proteins.

Methods

  • mESCs (AN3-12) were engineered with doxycycline-inducible Cas9 (iCas9v1/v2) and dual sgRNAs, plus AID- or dTAG-degron lines. Treatments included Dox 500 ng/ml, IAA 250 µM, dTAGv-1 500 nM, Epoxomicin 1 µM, and TAK-243 2.5 µM.
  • Readouts included competitive proliferation assays, Western blotting, RT-qPCR for PROMPTs, Northern blotting for rRNA processing intermediates, size-exclusion chromatography, immunoprecipitation, shotgun LC-MS/MS, and targeted PRM mass spectrometry.
  • Statistical analyses used two-way ANOVA with Holm–Šídák correction, limma with Benjamini–Hochberg correction, and biological replicates as indicated in figure legends.

Limitations

  • The paper states that SEC resolution limits definitive assignment of minimal assemblies; early heterogeneity is possible, such as Exosc2/7 dimers before the Exosc2/4/7 trimer, and the precise molecular nature of the post-Exosc3 rearrangement remains unresolved.
  • The paper notes that AID-tagging of Exosc3 caused a modest reduction in Exosc3 protein levels; one replicate was excluded as an outlier for sgExosc5 and the 90-min Exosc7 pull-down; and Dis3L was set to maximum observed co-depletion when no signal was detected in some samples.
  • Evident from the text: the assembly model is inferred from co-depletion, IP/SEC-MS, and kinetic enrichment in mESCs without structural validation of the intermediates; Exosc1-KO rRNA defects were more pronounced than with iCas9, attributed to terminal depletion effects.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s44318-026-00824-x

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 A dual-guide iCas9 system probes the essential cellular function of RNA exosome subunits in mESCs. (A) Outline of the experimental approach. Dual sgRNAs targeting RNA exosome subunits were delivered to iCas9 mESCs, followed by Puromycin (Puro) selection and Cas9 induction with doxycycline (Dox). (B) Schematic of the mammalian RNA exosome, highlighting core (cap and barrel) and catalytic subunits. “E” denotes Exosc subunits (e.g., E1 = Exosc1). (C) Western blot analysis of iCas9 mESCs expressing dual sgRNAs targeting the indicated RNA exosome component and treated with Dox for 0, 24, 48, and 72 h. Hsp70 serves as a loading control. Asterisk (*) indicates a non-specific band. (D) Western blot quantifications from (C) are shown as a heatmap. Protein levels were normalized to Hsp70 and expressed relative to the 0 h time point (n = 2 biological replicates). (E) Competitive proliferation assays of inducible Exosc knockout and Olfr10 (control) mESCs relative to a parental cell line. Data were normalized to Day0 and presented as mean ± SD (n = 3 biological replicates). See also Fig. EV1.
Figure 1 A dual-guide iCas9 system probes the essential cellular function of RNA exosome subunits in mESCs. (A) Outline of the experimental approach. Dual sgRNAs targeting RNA exosome subunits were delivered to iCas9 mESCs, followed by Puromycin (Puro) selection and Cas9 induction with doxycycline (Dox). (B) Schematic of the mammalian RNA exosome, highlighting core (cap and barrel) and catalytic subunits. “E” denotes Exosc subunits (e.g., E1 = Exosc1). (C) Western blot analysis of iCas9 mESCs expressing dual sgRNAs targeting the indicated RNA exosome component and treated with Dox for 0, 24, 48, and 72 h. Hsp70 serves as a loading control. Asterisk (*) indicates a non-specific band. (D) Western blot quantifications from (C) are shown as a heatmap. Protein levels were normalized to Hsp70 and expressed relative to the 0 h time point (n = 2 biological replicates). (E) Competitive proliferation assays of inducible Exosc knockout and Olfr10 (control) mESCs relative to a parental cell line. Data were normalized to Day0 and presented as mean ± SD (n = 3 biological replicates). See also Fig. EV1.CC BY · PubMed Central
Figure EV1 Establishment, validation, and benchmarking of a dual-guide iCas9 system to interrogate proteostatic dependencies among RNA exosome components, related to Figs. 1 and 2. (A) Schematic of the generation of clonal iCas9 cell lines. Roman numbers indicate vectors used for the engineering of the first (iCas9v1) and second (iCas9v2) versions of iCas9. For iCas9v1, expression cassettes for rtTA3 and Cas9 were packaged in lentiviruses and sequentially integrated into the genome. For iCas9v2, the “all-in-one” cassette was site-specifically integrated in the expression-stable locus on Chr15 (see Materials and Methods). (B) (Left): Flow cytometry evaluation of inducible Cas9 expression in iCas9v1 and iCas9v2 in the presence or absence of Dox. (Right): Evaluation of the editing efficiency of endogenously expressed YFP (iCas9v1) or surface marker CD9 (iCas9v2) in iCas9 cells transduced with the respective sgRNAs. For CD9 analysis, cells were immunostained before flow cytometry measurements. (C) iCas9 cells expressing different pairs of dual sgRNAs against Exosc1 (pair1–4) were treated with Dox for 0, 24, 48, and 72 h. Total proteins were analysed with Western blot against Exosc1 and Hsp70. Dilution series (5, 10, 25, 50, 100%) were used to estimate the sensitivity of the antibody, and Hsp70 served as a loading control. (D) Competitive proliferation assays of iCas9 cells harboring dual sgRNAs against Exosc1 (pair1–4) and Olfr10 (control). The percentage of sgRNA+ cells was monitored with flow cytometry. Values were normalized to Day0 and are represented as mean ± sd (n = 2 technical replicates). (E) Evaluation of the depletion efficiency of AID-tagged proteins upon IAA administration in AID-Exosc3 (top) and Exosc6-AID (bottom) cells. Tir1 (control) is a parental cell line that served as a negative control. Total proteins were analysed with Western blot using the indicated antibody. Dilution series (10, 25, 50, 100%) were used to estimate the sensitivity of the antibody, and actin represents a loading control. (F) Competitive proliferation assay of AID-Exosc3 (top) and Exosc6-AID (bottom) in the presence and absence of IAA. The percentage of AID-positive cells was monitored with flow cytometry. Values were normalized to Day0 and are represented as mean ± sd (n = 2 biological replicates). (G) Evaluation of the depletion efficiency of dTAG-tagged proteins upon dTAG administration in Exosc7-dTAG, Exosc8-dTAG and Exosc9-dTAG cells. Parental iCas9v2 cell line (control) served as a negative control. Total proteins were analysed with Western blot using the indicated antibody. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody, and actin represents a loading control. (H) Competitive proliferation assay of Exosc7-dTAG, Exosc8-dTAG, and Exosc9-dTAG cells in the presence and absence of dTAG. The percentage of dTAG-positive cells was monitored with flow cytometry. Values were normalized to Day0 and are represented as mean ± sd (n = 3 biological replicates). (I–T) iCas9 cells harboring dual sgRNAs against Exosc2 (I), Exosc4 (J), Exosc7 (K), Exosc6 (L), Exosc8 (M), Exosc9 (N), Exosc5 (O), Exosc3 (P), Exosc1 (Q), Exosc10 (R), Dis3L (S), and Dis3 (T) were treated with Dox for 0, 24, 48, and 72 h. Total proteins were analyzed with a Western blot for the indicated RNA exosome components. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody, and Hsp70 served as a loading control. Black asterisk (*) refers to the corresponding gel and purple asterisk (*) indicates a nonspecific band.
Figure EV1 Establishment, validation, and benchmarking of a dual-guide iCas9 system to interrogate proteostatic dependencies among RNA exosome components, related to Figs. 1 and 2. (A) Schematic of the generation of clonal iCas9 cell lines. Roman numbers indicate vectors used for the engineering of the first (iCas9v1) and second (iCas9v2) versions of iCas9. For iCas9v1, expression cassettes for rtTA3 and Cas9 were packaged in lentiviruses and sequentially integrated into the genome. For iCas9v2, the “all-in-one” cassette was site-specifically integrated in the expression-stable locus on Chr15 (see Materials and Methods). (B) (Left): Flow cytometry evaluation of inducible Cas9 expression in iCas9v1 and iCas9v2 in the presence or absence of Dox. (Right): Evaluation of the editing efficiency of endogenously expressed YFP (iCas9v1) or surface marker CD9 (iCas9v2) in iCas9 cells transduced with the respective sgRNAs. For CD9 analysis, cells were immunostained before flow cytometry measurements. (C) iCas9 cells expressing different pairs of dual sgRNAs against Exosc1 (pair1–4) were treated with Dox for 0, 24, 48, and 72 h. Total proteins were analysed with Western blot against Exosc1 and Hsp70. Dilution series (5, 10, 25, 50, 100%) were used to estimate the sensitivity of the antibody, and Hsp70 served as a loading control. (D) Competitive proliferation assays of iCas9 cells harboring dual sgRNAs against Exosc1 (pair1–4) and Olfr10 (control). The percentage of sgRNA+ cells was monitored with flow cytometry. Values were normalized to Day0 and are represented as mean ± sd (n = 2 technical replicates). (E) Evaluation of the depletion efficiency of AID-tagged proteins upon IAA administration in AID-Exosc3 (top) and Exosc6-AID (bottom) cells. Tir1 (control) is a parental cell line that served as a negative control. Total proteins were analysed with Western blot using the indicated antibody. Dilution series (10, 25, 50, 100%) were used to estimate the sensitivity of the antibody, and actin represents a loading control. (F) Competitive proliferation assay of AID-Exosc3 (top) and Exosc6-AID (bottom) in the presence and absence of IAA. The percentage of AID-positive cells was monitored with flow cytometry. Values were normalized to Day0 and are represented as mean ± sd (n = 2 biological replicates). (G) Evaluation of the depletion efficiency of dTAG-tagged proteins upon dTAG administration in Exosc7-dTAG, Exosc8-dTAG and Exosc9-dTAG cells. Parental iCas9v2 cell line (control) served as a negative control. Total proteins were analysed with Western blot using the indicated antibody. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody, and actin represents a loading control. (H) Competitive proliferation assay of Exosc7-dTAG, Exosc8-dTAG, and Exosc9-dTAG cells in the presence and absence of dTAG. The percentage of dTAG-positive cells was monitored with flow cytometry. Values were normalized to Day0 and are represented as mean ± sd (n = 3 biological replicates). (I–T) iCas9 cells harboring dual sgRNAs against Exosc2 (I), Exosc4 (J), Exosc7 (K), Exosc6 (L), Exosc8 (M), Exosc9 (N), Exosc5 (O), Exosc3 (P), Exosc1 (Q), Exosc10 (R), Dis3L (S), and Dis3 (T) were treated with Dox for 0, 24, 48, and 72 h. Total proteins were analyzed with a Western blot for the indicated RNA exosome components. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody, and Hsp70 served as a loading control. Black asterisk (*) refers to the corresponding gel and purple asterisk (*) indicates a nonspecific band.CC BY · PubMed Central
Figure 2 Proteolytic degradation of orphan subunits by the ubiquitin-proteasome system reveals an ordered cellular assembly of the RNA exosome. (A) Western blot analysis was performed on iCas9 mESCs harboring dual sgRNAs targeting the indicated RNA exosome components or Olfr1 and Olfr10 (controls), treated with Dox for 72 h. Tubulin serves as a loading control. Asterisk (*) indicate matching membranes. (B) Relative abundance of RNA exosome subunits was assessed 72 h after induction of sgRNAs targeting the indicated Exosc, normalized to sgOlfr1 control. Protein abundance was determined by shotgun or targeted mass-spectrometry. Values are shown relative to sgOlfr1 control sample. Statistical significance was determined using two-way ANOVA with Holm-Šídák multiple comparison correction. Black dots indicate instances where log2FC <−1 or log2FC >1 and padj < 0.05. (C) Auxin-inducible degradation of Exosc6 was analysed in Exosc6-AID mESCs treated with IAA for the indicated time in hours (h). Actin serves as a loading control. Asterisk (*) refers to matching membranes. (D) Western blot quantifications from (C) were normalized to Actin and expressed relative to untreated Exosc6-AID mESCs (n = 2 biological replicates). Statistical significance was determined using two-way ANOVA with Holm–Šídák multiple comparison correction. Black dots indicate instances where padj < 0.05. (E) Western blot analysis was performed on iCas9 mESCs harboring dual sgRNAs targeting Exosc2 treated with Dox for 42 h, followed by 6 h of DMSO, Epoxomicin and TAK-243 treatment. Actin serves as a loading control. (F) Western blot quantifications from (E) were normalized to Actin and expressed relative to DMSO control as mean ± sd (n = 3 biological replicates). Statistical significance was determined using two-way ANOVA with Holm–Šídák multiple comparison correction (*padj < 0.05, **padj < 0.01, ***padj < 0.001, ****padj < 0.0001). P values = 0.0187 and 0.0132 (DMSO vs Epoxomicin from top to bottom); 0.0045, 0.0032, and 0.0096 (DMSO vs TAK-243 from top to bottom). (G) Model of the cellular assembly of the RNA exosome. See text for details. See also Fig. EV1; Dataset EV1.
Figure 2 Proteolytic degradation of orphan subunits by the ubiquitin-proteasome system reveals an ordered cellular assembly of the RNA exosome. (A) Western blot analysis was performed on iCas9 mESCs harboring dual sgRNAs targeting the indicated RNA exosome components or Olfr1 and Olfr10 (controls), treated with Dox for 72 h. Tubulin serves as a loading control. Asterisk (*) indicate matching membranes. (B) Relative abundance of RNA exosome subunits was assessed 72 h after induction of sgRNAs targeting the indicated Exosc, normalized to sgOlfr1 control. Protein abundance was determined by shotgun or targeted mass-spectrometry. Values are shown relative to sgOlfr1 control sample. Statistical significance was determined using two-way ANOVA with Holm-Šídák multiple comparison correction. Black dots indicate instances where log2FC <−1 or log2FC >1 and padj < 0.05. (C) Auxin-inducible degradation of Exosc6 was analysed in Exosc6-AID mESCs treated with IAA for the indicated time in hours (h). Actin serves as a loading control. Asterisk (*) refers to matching membranes. (D) Western blot quantifications from (C) were normalized to Actin and expressed relative to untreated Exosc6-AID mESCs (n = 2 biological replicates). Statistical significance was determined using two-way ANOVA with Holm–Šídák multiple comparison correction. Black dots indicate instances where padj < 0.05. (E) Western blot analysis was performed on iCas9 mESCs harboring dual sgRNAs targeting Exosc2 treated with Dox for 42 h, followed by 6 h of DMSO, Epoxomicin and TAK-243 treatment. Actin serves as a loading control. (F) Western blot quantifications from (E) were normalized to Actin and expressed relative to DMSO control as mean ± sd (n = 3 biological replicates). Statistical significance was determined using two-way ANOVA with Holm–Šídák multiple comparison correction (*padj < 0.05, **padj < 0.01, ***padj < 0.001, ****padj < 0.0001). P values = 0.0187 and 0.0132 (DMSO vs Epoxomicin from top to bottom); 0.0045, 0.0032, and 0.0096 (DMSO vs TAK-243 from top to bottom). (G) Model of the cellular assembly of the RNA exosome. See text for details. See also Fig. EV1; Dataset EV1.CC BY · PubMed Central
Figure EV2 Rapid depletion of RNA exosome subunits and interrogation of RNA exosome assembly intermediates, related to Figs. 2 and 3. (A–C) Exosc7-dTAG (A), Exosc8-dTAG (B), and Exosc9-dTAG (C) cells were treated with dTAG for the indicated period pf time. Parental iCas9v2 cell line (control) served as a negative control. Total proteins were analyzed with Western blot using the indicated antibody. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody, and Actin served as a loading control. (D) Parental Tir1 (ctrl) and AID-Exosc3 cells were treated with IAA for the indicated period of time. Total proteins were analyzed with Western blot using the indicated antibody. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody, and Actin served as a loading control. Asterisk (*) refers to the corresponding gel. (E) Control V5-mCherry-P2A-eBFP2 or Exosc2-mCherry-V5-P2A-eBFP2 cassettes were lentivirally delivered to iCas9 cells, followed by Blasticidin S (BSD) selection. (F) Western blot analysis of the cell lines from (A) with αV5 and αExosc2 antibody. Tubulin served as a loading control. Black asterisk (*) refers to the corresponding gel. Purple asterisk (*) indicates the signal from V5-mCherry-P2A-eBFP2. (G) Mass-spectrometry analysis of αV5-immunoprecipitation from Exosc2-mCherry-V5 or V5-mCherry control samples. The log2 fold change (x axis) is plotted against the −log10 of Benjamini–Hochberg adjusted limma-moderated two-sided t-test p value (y axis; padj). Dashed lines indicate the thresholds of padj < 0.05 and log2FC <−1 or >1 (n = 3 biological replicates). (H) Generation of ectopic expression of Exosc2-mScarlet3-SPOT in the parental Tir1 (ctrl), AID-Exosc3, and Exosc6-AID cell lines. The cassette was virally delivered, and cells were selected with Blasticidin S (BSD). (I) αSPOT-IP of cells from (H). Input and bead-bound proteins were analyzed with a Western blot using the indicated antibody. Tubulin served as a loading control. (J) Total protein extract of wild-type mESCs was subjected to size-exclusion chromatography followed by western blot analysis using the indicated antibodies. (K) Generation and validation of Exosc2-HA-mNeonGreen (labeled as Exosc2-L-HA-mNG) knockout-rescue clonal cell line. Total protein was analyzed with a Western blot using the indicated antibodies. (L) Total protein extract of Exosc2-HA-mNeonGreen and untagged parental control was subjected to size-exclusion chromatography, and indicated fractions were pooled, followed by αHA-immunoprecipitation and mass-spectrometry analysis. The log2 fold change (x axis) is plotted against the −log10 of Benjamini–Hochberg adjusted limma-moderated two-sided t-test p value (y axis; padj). Dashed lines indicate the threshold of padj < 0.05 and log2FC >2 (n = 3 biological replicates). (M) Cells harboring doxycycline-inducible Exosc7-3xFLAG cassette were subjected to doxycycline (Dox) treatment for the indicated period of time, followed by western blot analysis. Vinculin served as a loading control.
Figure EV2 Rapid depletion of RNA exosome subunits and interrogation of RNA exosome assembly intermediates, related to Figs. 2 and 3. (A–C) Exosc7-dTAG (A), Exosc8-dTAG (B), and Exosc9-dTAG (C) cells were treated with dTAG for the indicated period pf time. Parental iCas9v2 cell line (control) served as a negative control. Total proteins were analyzed with Western blot using the indicated antibody. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody, and Actin served as a loading control. (D) Parental Tir1 (ctrl) and AID-Exosc3 cells were treated with IAA for the indicated period of time. Total proteins were analyzed with Western blot using the indicated antibody. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody, and Actin served as a loading control. Asterisk (*) refers to the corresponding gel. (E) Control V5-mCherry-P2A-eBFP2 or Exosc2-mCherry-V5-P2A-eBFP2 cassettes were lentivirally delivered to iCas9 cells, followed by Blasticidin S (BSD) selection. (F) Western blot analysis of the cell lines from (A) with αV5 and αExosc2 antibody. Tubulin served as a loading control. Black asterisk (*) refers to the corresponding gel. Purple asterisk (*) indicates the signal from V5-mCherry-P2A-eBFP2. (G) Mass-spectrometry analysis of αV5-immunoprecipitation from Exosc2-mCherry-V5 or V5-mCherry control samples. The log2 fold change (x axis) is plotted against the −log10 of Benjamini–Hochberg adjusted limma-moderated two-sided t-test p value (y axis; padj). Dashed lines indicate the thresholds of padj < 0.05 and log2FC <−1 or >1 (n = 3 biological replicates). (H) Generation of ectopic expression of Exosc2-mScarlet3-SPOT in the parental Tir1 (ctrl), AID-Exosc3, and Exosc6-AID cell lines. The cassette was virally delivered, and cells were selected with Blasticidin S (BSD). (I) αSPOT-IP of cells from (H). Input and bead-bound proteins were analyzed with a Western blot using the indicated antibody. Tubulin served as a loading control. (J) Total protein extract of wild-type mESCs was subjected to size-exclusion chromatography followed by western blot analysis using the indicated antibodies. (K) Generation and validation of Exosc2-HA-mNeonGreen (labeled as Exosc2-L-HA-mNG) knockout-rescue clonal cell line. Total protein was analyzed with a Western blot using the indicated antibodies. (L) Total protein extract of Exosc2-HA-mNeonGreen and untagged parental control was subjected to size-exclusion chromatography, and indicated fractions were pooled, followed by αHA-immunoprecipitation and mass-spectrometry analysis. The log2 fold change (x axis) is plotted against the −log10 of Benjamini–Hochberg adjusted limma-moderated two-sided t-test p value (y axis; padj). Dashed lines indicate the threshold of padj < 0.05 and log2FC >2 (n = 3 biological replicates). (M) Cells harboring doxycycline-inducible Exosc7-3xFLAG cassette were subjected to doxycycline (Dox) treatment for the indicated period of time, followed by western blot analysis. Vinculin served as a loading control.CC BY · PubMed Central
Figure 3 RNA exosome assembly intermediates form biochemically tractable subcomplexes and are present in wild-type cells. (A) V5-Immunoprecipitation (IP) was performed on the lysate of mESCs expressing V5-mCherry-P2A-eBFP2 (control) or Exosc2-mCherry-V5-P2A-eBFP2. Tubulin serves as a loading control. Black asterisk (*) refers to matching membranes. Purple asterisk (*) refers to unprocessed V5-mCherry-P2A-eBFP2. I indicates input and B indicates bead-bound proteins. (B–H) RNA exosome assembly intermediates were analysed in the lysate of mESCs expressing Exosc2-mCherry-V5-P2A-eBFP2, upon dual sgRNA-mediated depletion of Exosc6 (B), Exosc8 (C), Exosc9 (D), Exosc5 (E), Exosc3 (F), Exosc1 (G), or control Olfr10 (H) for the indicated time (in hours, h). αV5-IP was performed, and input and bead-bound proteins were analysed by Western blotting. Schematics depict expected RNA exosome assembly intermediates. Asterisk (*) refers to matching membranes. (I) HA-immunoprecipitation of Exosc2-HA-mNeonGreen from the indicated size-exclusion chromatography fractions. Protein abundance was quantified by mass-spectrometry relative to the untagged control, normalized to Exosc2 bait and presented relative to the heavy A7–A10 fractions as mean ± sd (n = 3 biological replicates). (J) FLAG-immunoprecipitation of doxycycline-inducible Exosc7-3xFLAG at the indicated time-points. Protein abundance was quantified by mass-spectrometry, and enrichment was calculated relative to the untagged control. Black dots indicate instances with log2FC >1.5 and padj < 0.05. See also Fig. EV2; Datasets EV3 and EV4.
Figure 3 RNA exosome assembly intermediates form biochemically tractable subcomplexes and are present in wild-type cells. (A) V5-Immunoprecipitation (IP) was performed on the lysate of mESCs expressing V5-mCherry-P2A-eBFP2 (control) or Exosc2-mCherry-V5-P2A-eBFP2. Tubulin serves as a loading control. Black asterisk (*) refers to matching membranes. Purple asterisk (*) refers to unprocessed V5-mCherry-P2A-eBFP2. I indicates input and B indicates bead-bound proteins. (B–H) RNA exosome assembly intermediates were analysed in the lysate of mESCs expressing Exosc2-mCherry-V5-P2A-eBFP2, upon dual sgRNA-mediated depletion of Exosc6 (B), Exosc8 (C), Exosc9 (D), Exosc5 (E), Exosc3 (F), Exosc1 (G), or control Olfr10 (H) for the indicated time (in hours, h). αV5-IP was performed, and input and bead-bound proteins were analysed by Western blotting. Schematics depict expected RNA exosome assembly intermediates. Asterisk (*) refers to matching membranes. (I) HA-immunoprecipitation of Exosc2-HA-mNeonGreen from the indicated size-exclusion chromatography fractions. Protein abundance was quantified by mass-spectrometry relative to the untagged control, normalized to Exosc2 bait and presented relative to the heavy A7–A10 fractions as mean ± sd (n = 3 biological replicates). (J) FLAG-immunoprecipitation of doxycycline-inducible Exosc7-3xFLAG at the indicated time-points. Protein abundance was quantified by mass-spectrometry, and enrichment was calculated relative to the untagged control. Black dots indicate instances with log2FC >1.5 and padj < 0.05. See also Fig. EV2; Datasets EV3 and EV4.CC BY · PubMed Central
Figure 4 Functional assessment of RNA exosome assembly intermediates. (A) Schematic represents promoter upstream transcripts (PROMPTs), transcribed from the antisense strand upstream of active gene promoters. (B) Reverse transcription quantitative PCR (RT-qPCR) analysis of PROMPTs was performed in mESCs expressing dual sgRNAs targeting the indicated RNA exosome subunit upon treatment with Dox for 72 h. Values were normalized to Gapdh mRNA and expressed relative to sgOlfr10 control. Bargraph reports mean ± SD of three independent replicates; individual measurements are indicated. Statistical significance was determined using two-way ANOVA with Holm–Šídák multiple comparison correction. (*padj < 0.05, **padj < 0.0021, ***padj < 0.0002, ****padj < 0.0001). Exact adjusted p values (sgOlfr10 vs indicated condition): proRpl23: 7.4 × 10−4 (Exosc1), <1.0 × 10−15 (Exosc2), <1.0 × 10−15 (Exosc3), <1.0 × 10−15 (Exosc4), <1.0 × 10−15 (Exosc5), <1.0 × 10−15 (Exosc6), <1.0 × 10−15 (Exosc7), <1.0 × 10−15 (Exosc8), <1.0 × 10−15 (Exosc9), 5.4 × 10−4 (Exosc10), <1.0 × 10−15 (Dis3); proPou5f1: 4.1 × 10−4 (Exosc1), <1.0 × 10−15 (Exosc2), 7.6 × 10−14 (Exosc3), <1.0 × 10−15 (Exosc4), 1.5 × 10−13 (Exosc5), 5.0 × 10−15 (Exosc6), <1.0 × 10−15 (Exosc7), <1.0 × 10−15 (Exosc8), <1.0 × 10−15 (Exosc9), 9.9 × 10−5 (Exosc10), <1.0 × 10−15 (Dis3); proAnkhd1: 2.2 × 10−2 (Exosc1), <1.0 × 10−15 (Exosc2), 4.9 × 10−11 (Exosc3), <1.0 × 10−15 (Exosc4), 9.1 × 10−10 (Exosc5), <1.0 × 10−15 (Exosc6), <1.0 × 10−15 (Exosc7), <1.0 × 10−15 (Exosc8), <1.0 × 10−15 (Exosc9), 2.21 × 10−2 (Exosc10), <1.0 × 10−15 (Dis3); Fam120aos: 6.1 × 10−3 (Exosc1), 2.0 × 10−15 (Exosc2), 1.2 × 10−12 (Exosc3), <1.0 × 10−15 (Exosc4), 6.3 × 10−12 (Exosc5), <1.0 × 10−15 (Exosc6), <1.0 × 10−15 (Exosc7), <1.0 × 10−15 (Exosc8), <1.0 × 10−15 (Exosc9), 4.6 × 10⁻³ (Exosc10), <1.0 × 10−15 (Dis3). (C) A schematic of rRNA processing intermediates is shown. Individual probes are indicated. (D) Northern blot analysis was performed on total RNA extracted from iCas9 mESCs expressing dual sgRNAs targeting the indicated RNA exosome subunits or Olfr10 control 72 h after Dox treatment to detect the indicated rRNA processing intermediates. Probes used are shown in (C). (E) Average change in the abundance of rRNA processing intermediates as detected in (D), with rRNA intermediate abundance normalized to 7SK RNA and expressed relative to control (n = 3 biological replicates). Statistical significance was determined using two-way ANOVA with Holm–Šídák multiple comparison correction. Black dots indicate instances where padj < 0.05. (F) Western blot analysis was performed on the lysate of iCas9 mESCs expressing dual sgRNAs targeting Olfr10 (control), Exosc1, Exosc2, and Exosc6, and treated with Dox for 72 h. Tubulin serves as a loading control. (G) Quantification of (F), with protein abundance normalized to Tubulin and expressed relative to sgOlfr10 control as mean ± sd (n = 3 biological replicates). Statistical significance was determined using two-way ANOVA with Holm–Šídák multiple comparison correction (*padj < 0.05, **padj < 0.0021, ***padj < 0.0002, ****padj < 0.0001). Exact adjusted p values (sgOlfr10 vs indicated condition): PARP: 1.29 × 10⁻6 (Exosc2), 5.14 × 10⁻6 (Exosc26; Cleaved PARP: 3.13 × 10⁻² (Exosc1), 2.85 × 10⁻10 (Exosc2), 2.85 × 10⁻10 (Exosc6); Cleaved Caspase3: 1.25 × 10⁻12 (Exosc1), 1.25 × 10⁻12 (Exosc2). See also Figs. EV3–EV5; Dataset EV5.
Figure 4 Functional assessment of RNA exosome assembly intermediates. (A) Schematic represents promoter upstream transcripts (PROMPTs), transcribed from the antisense strand upstream of active gene promoters. (B) Reverse transcription quantitative PCR (RT-qPCR) analysis of PROMPTs was performed in mESCs expressing dual sgRNAs targeting the indicated RNA exosome subunit upon treatment with Dox for 72 h. Values were normalized to Gapdh mRNA and expressed relative to sgOlfr10 control. Bargraph reports mean ± SD of three independent replicates; individual measurements are indicated. Statistical significance was determined using two-way ANOVA with Holm–Šídák multiple comparison correction. (*padj < 0.05, **padj < 0.0021, ***padj < 0.0002, ****padj < 0.0001). Exact adjusted p values (sgOlfr10 vs indicated condition): proRpl23: 7.4 × 10−4 (Exosc1), <1.0 × 10−15 (Exosc2), <1.0 × 10−15 (Exosc3), <1.0 × 10−15 (Exosc4), <1.0 × 10−15 (Exosc5), <1.0 × 10−15 (Exosc6), <1.0 × 10−15 (Exosc7), <1.0 × 10−15 (Exosc8), <1.0 × 10−15 (Exosc9), 5.4 × 10−4 (Exosc10), <1.0 × 10−15 (Dis3); proPou5f1: 4.1 × 10−4 (Exosc1), <1.0 × 10−15 (Exosc2), 7.6 × 10−14 (Exosc3), <1.0 × 10−15 (Exosc4), 1.5 × 10−13 (Exosc5), 5.0 × 10−15 (Exosc6), <1.0 × 10−15 (Exosc7), <1.0 × 10−15 (Exosc8), <1.0 × 10−15 (Exosc9), 9.9 × 10−5 (Exosc10), <1.0 × 10−15 (Dis3); proAnkhd1: 2.2 × 10−2 (Exosc1), <1.0 × 10−15 (Exosc2), 4.9 × 10−11 (Exosc3), <1.0 × 10−15 (Exosc4), 9.1 × 10−10 (Exosc5), <1.0 × 10−15 (Exosc6), <1.0 × 10−15 (Exosc7), <1.0 × 10−15 (Exosc8), <1.0 × 10−15 (Exosc9), 2.21 × 10−2 (Exosc10), <1.0 × 10−15 (Dis3); Fam120aos: 6.1 × 10−3 (Exosc1), 2.0 × 10−15 (Exosc2), 1.2 × 10−12 (Exosc3), <1.0 × 10−15 (Exosc4), 6.3 × 10−12 (Exosc5), <1.0 × 10−15 (Exosc6), <1.0 × 10−15 (Exosc7), <1.0 × 10−15 (Exosc8), <1.0 × 10−15 (Exosc9), 4.6 × 10⁻³ (Exosc10), <1.0 × 10−15 (Dis3). (C) A schematic of rRNA processing intermediates is shown. Individual probes are indicated. (D) Northern blot analysis was performed on total RNA extracted from iCas9 mESCs expressing dual sgRNAs targeting the indicated RNA exosome subunits or Olfr10 control 72 h after Dox treatment to detect the indicated rRNA processing intermediates. Probes used are shown in (C). (E) Average change in the abundance of rRNA processing intermediates as detected in (D), with rRNA intermediate abundance normalized to 7SK RNA and expressed relative to control (n = 3 biological replicates). Statistical significance was determined using two-way ANOVA with Holm–Šídák multiple comparison correction. Black dots indicate instances where padj < 0.05. (F) Western blot analysis was performed on the lysate of iCas9 mESCs expressing dual sgRNAs targeting Olfr10 (control), Exosc1, Exosc2, and Exosc6, and treated with Dox for 72 h. Tubulin serves as a loading control. (G) Quantification of (F), with protein abundance normalized to Tubulin and expressed relative to sgOlfr10 control as mean ± sd (n = 3 biological replicates). Statistical significance was determined using two-way ANOVA with Holm–Šídák multiple comparison correction (*padj < 0.05, **padj < 0.0021, ***padj < 0.0002, ****padj < 0.0001). Exact adjusted p values (sgOlfr10 vs indicated condition): PARP: 1.29 × 10⁻6 (Exosc2), 5.14 × 10⁻6 (Exosc26; Cleaved PARP: 3.13 × 10⁻² (Exosc1), 2.85 × 10⁻10 (Exosc2), 2.85 × 10⁻10 (Exosc6); Cleaved Caspase3: 1.25 × 10⁻12 (Exosc1), 1.25 × 10⁻12 (Exosc2). See also Figs. EV3–EV5; Dataset EV5.CC BY · PubMed Central
Figure EV3 Stabilization of PROMPTs and accumulation of rRNA processing defects upon depletion of Exosc3 and Exosc6 by AID, related to Fig. 4. (A, B) Parental Tir1 (ctrl), AID-Exosc3 (A) and Exosc6-AID (B) cells were treated with IAA for the indicated time period. Total RNA was isolated, and PROMPTs abundance was measured with RT-qPCR. Values were normalized to Gapdh mRNA, and mean ± sd is shown relative to ctrl 0 h IAA (n = 3 biological replicates for AID-Exosc3 (A) and n = 2 biological replicates for AID-Exosc6 (B)). Statistical significance of the difference between a given sample and “0 h IAA ctrl” was determined with a two-way ANOVA test and Holm–Šídák multiple comparison correction (*padj < 0.05, **padj < 0.0021, ***padj < 0.0002, ****padj < 0.0001, non-significant padj > 0.05 is not marked). Exact adjusted p values: (A) AID-Exosc3 vs control (0 h IAA): proRpl23: 1.38 × 10⁻⁴, 5.4 × 10⁻7, 2.23 × 10⁻8, 4.34 × 10⁻10, 5.89 × 10⁻10; proPou5f1: 2.44 × 10⁻8, 3.92 × 10⁻8, 2.33 × 10⁻8, 9.57 × 10⁻9, 6.55 × 10⁻9; proAnkhd1: 2.53 × 10⁻⁴, 4.94 × 10⁻6, 4.35 × 10⁻8; Fam120aos: 3.38 × 10⁻2, 1.85 × 10⁻⁴, 2.80 × 10⁻7, 5.28 × 10⁻9; (B) Exosc6-AID vs control (0 h IAA): proRpl23: <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15; proPou5f1: <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15; proAnkhd1: 8.75 × 10−8, 4.42 × 10−11, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15; Fam120aos: 1.95 × 10−3, 3.64 × 10−11, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15. (C,D) Parental Tir1 (ctrl), AID-Exosc3 (C) and Exosc6-AID (D) cells were treated with IAA for the indicated time period. Total RNA was resolved on the agarose gel, followed by northern blot analysis. (E,F) Heatmap of northern blot quantifications for AID-Exosc3 (E) and Exosc6-AID (F). Abundance of rRNA processing intermediates was normalized to 7SK RNA, and the mean is shown relative to untreated AID-Exosc3 or Exosc6-AID samples (n = 3 for AID-Exosc3 and n = 2 for Exosc6-AID biological replicates). Statistical significance of the difference between a given sample and untreated AID-Exosc3 or Exosc6-AID controls was determined with a two-way ANOVA test and Holm–Šídák multiple comparison correction. Black dots indicate instances with padj < 0.05.
Figure EV3 Stabilization of PROMPTs and accumulation of rRNA processing defects upon depletion of Exosc3 and Exosc6 by AID, related to Fig. 4. (A, B) Parental Tir1 (ctrl), AID-Exosc3 (A) and Exosc6-AID (B) cells were treated with IAA for the indicated time period. Total RNA was isolated, and PROMPTs abundance was measured with RT-qPCR. Values were normalized to Gapdh mRNA, and mean ± sd is shown relative to ctrl 0 h IAA (n = 3 biological replicates for AID-Exosc3 (A) and n = 2 biological replicates for AID-Exosc6 (B)). Statistical significance of the difference between a given sample and “0 h IAA ctrl” was determined with a two-way ANOVA test and Holm–Šídák multiple comparison correction (*padj < 0.05, **padj < 0.0021, ***padj < 0.0002, ****padj < 0.0001, non-significant padj > 0.05 is not marked). Exact adjusted p values: (A) AID-Exosc3 vs control (0 h IAA): proRpl23: 1.38 × 10⁻⁴, 5.4 × 10⁻7, 2.23 × 10⁻8, 4.34 × 10⁻10, 5.89 × 10⁻10; proPou5f1: 2.44 × 10⁻8, 3.92 × 10⁻8, 2.33 × 10⁻8, 9.57 × 10⁻9, 6.55 × 10⁻9; proAnkhd1: 2.53 × 10⁻⁴, 4.94 × 10⁻6, 4.35 × 10⁻8; Fam120aos: 3.38 × 10⁻2, 1.85 × 10⁻⁴, 2.80 × 10⁻7, 5.28 × 10⁻9; (B) Exosc6-AID vs control (0 h IAA): proRpl23: <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15; proPou5f1: <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15; proAnkhd1: 8.75 × 10−8, 4.42 × 10−11, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15; Fam120aos: 1.95 × 10−3, 3.64 × 10−11, <1.0 × 10−15, <1.0 × 10−15, <1.0 × 10−15. (C,D) Parental Tir1 (ctrl), AID-Exosc3 (C) and Exosc6-AID (D) cells were treated with IAA for the indicated time period. Total RNA was resolved on the agarose gel, followed by northern blot analysis. (E,F) Heatmap of northern blot quantifications for AID-Exosc3 (E) and Exosc6-AID (F). Abundance of rRNA processing intermediates was normalized to 7SK RNA, and the mean is shown relative to untreated AID-Exosc3 or Exosc6-AID samples (n = 3 for AID-Exosc3 and n = 2 for Exosc6-AID biological replicates). Statistical significance of the difference between a given sample and untreated AID-Exosc3 or Exosc6-AID controls was determined with a two-way ANOVA test and Holm–Šídák multiple comparison correction. Black dots indicate instances with padj < 0.05.CC BY · PubMed Central
Figure EV4 Establishment, validation and characterization of mESC lines depleted of Exosc1 by CRISPR/Cas9 genome engineering, related to Fig. 4. (A) Schematic of Exosc1 genomic loci. Frameshift mutations were introduced in the second coding exon with the CRISPR/Cas9 system. Genotypes of three Exosc1-KO clones used in this study are indicated. (B) Western blot analysis of wild-type and clonal Exosc1-KO cell lines. Dilution series (10, 25, 50, 100%) were used to estimate the sensitivity of the antibody, and actin represents a loading control. (C) Protein sequence of Exosc1. Six peptides that were measured with parallel reaction monitoring (PRM) mass-spectrometry are highlighted with blue rectangles and labeled with roman numbers (I-VI). (D) Example PRM analysis of wild-type and Exosc1-KO cells for the peptide II. PRM intensity signal (y-axis) is plotted against the retention time (x-axis). Multiple curves correspond to MS/MS = MS2 fragments. (E) Example PRM analysis of one of the peptides of the Cct8 protein that served as a “loading control”. Data were represented as in (D). See Materials and methods for information about the reference proteins used in PRM experiments. (F) PRM signal intensity of Exosc1 peptides in wild-type and Exosc1-KO cells shown as mean ± sd. No signal was detected in Exosc1-KO samples and is depicted as n.d. (not determined; n = 3 biological replicates). (G) Competitive proliferation assay of wild-type and Exosc1-KO cells. The percentage of wild-type or Exosc1-KO cells was monitored with flow cytometry. Values were normalized to Day0 and are shown as mean ± sd (n = 2 technical replicates). (H) Schematic of Exosc1 rescue experiments. Rescue constructs harboring mCherry-V5 or V5-Exosc1 or Exosc1-V5 were virally delivered to Exosc1-KO cells, followed by G418 selection. (I) Western blot analysis of the cells with rescue constructs. Membranes were probed with αV5 and αExosc1 antibody to confirm transgene expression. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody, and actin served as a loading control. (J) Competitive proliferation assay, as in (G), for Exosc1 rescue cells. (K,L) Total RNA from wild-type, Exosc1-KO (K) and rescue (L) experiments was isolated, and PROMPTs abundance was measured with RT-qPCR. Values were normalized to Gapdh mRNA, and mean ± sd is shown relative to wild-type (n = 3 biological replicates). Statistical significance of the difference between a given sample and wild-type was determined with an unpaired t-test (for K) or two-way ANOVA (for L) and Holm-Šídák multiple comparison correction. (n = 3 biological replicates, (*padj < 0.05, **padj < 0.0021, ***padj < 0.0002, ****padj < 0.0001, non-significant padj > 0.05 is not marked). Exact adjusted p values: (K) WT vs Exosc1-KO: 2.0 × 10⁻⁴, 7.0 × 10⁻⁴, 7.9 × 10⁻³, 2.2 × 10⁻²; (L) WT vs Exosc1-KO: 3.38 × 10⁻7, 4.42 × 10⁻13, 8.73 × 10⁻6, 3.73 × 10⁻7; WT vs Exosc1-KO + mCherry-V5: 1.14 × 10⁻7, 5.8 × 10⁻14, 6.05 × 10⁻7, 9.57 × 10⁻8; WT vs Exosc1-KO + Exosc1-V5: 4.34 × 10⁻². (M, N) Total RNA from wild-type, Exosc1-KO (M) and rescue (N) experiments was resolved on the agarose gel, followed by northern blot analysis. (O,P) Heatmap of northern blot quantifications for wild-type, Exosc1-KO (O) and rescue (P) experiments. Values were normalized to 7SK RNA, and the mean is presented relative to wild-type (n = 3 biological replicates). Statistical significance of the difference between a given sample and wild-type was determined with an unpaired t-test (for O) or two-way ANOVA (for P) and Holm–Šídák multiple comparison correction (n = 3 biological replicates. Black dots indicate instances with padj < 0.05.
Figure EV4 Establishment, validation and characterization of mESC lines depleted of Exosc1 by CRISPR/Cas9 genome engineering, related to Fig. 4. (A) Schematic of Exosc1 genomic loci. Frameshift mutations were introduced in the second coding exon with the CRISPR/Cas9 system. Genotypes of three Exosc1-KO clones used in this study are indicated. (B) Western blot analysis of wild-type and clonal Exosc1-KO cell lines. Dilution series (10, 25, 50, 100%) were used to estimate the sensitivity of the antibody, and actin represents a loading control. (C) Protein sequence of Exosc1. Six peptides that were measured with parallel reaction monitoring (PRM) mass-spectrometry are highlighted with blue rectangles and labeled with roman numbers (I-VI). (D) Example PRM analysis of wild-type and Exosc1-KO cells for the peptide II. PRM intensity signal (y-axis) is plotted against the retention time (x-axis). Multiple curves correspond to MS/MS = MS2 fragments. (E) Example PRM analysis of one of the peptides of the Cct8 protein that served as a “loading control”. Data were represented as in (D). See Materials and methods for information about the reference proteins used in PRM experiments. (F) PRM signal intensity of Exosc1 peptides in wild-type and Exosc1-KO cells shown as mean ± sd. No signal was detected in Exosc1-KO samples and is depicted as n.d. (not determined; n = 3 biological replicates). (G) Competitive proliferation assay of wild-type and Exosc1-KO cells. The percentage of wild-type or Exosc1-KO cells was monitored with flow cytometry. Values were normalized to Day0 and are shown as mean ± sd (n = 2 technical replicates). (H) Schematic of Exosc1 rescue experiments. Rescue constructs harboring mCherry-V5 or V5-Exosc1 or Exosc1-V5 were virally delivered to Exosc1-KO cells, followed by G418 selection. (I) Western blot analysis of the cells with rescue constructs. Membranes were probed with αV5 and αExosc1 antibody to confirm transgene expression. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody, and actin served as a loading control. (J) Competitive proliferation assay, as in (G), for Exosc1 rescue cells. (K,L) Total RNA from wild-type, Exosc1-KO (K) and rescue (L) experiments was isolated, and PROMPTs abundance was measured with RT-qPCR. Values were normalized to Gapdh mRNA, and mean ± sd is shown relative to wild-type (n = 3 biological replicates). Statistical significance of the difference between a given sample and wild-type was determined with an unpaired t-test (for K) or two-way ANOVA (for L) and Holm-Šídák multiple comparison correction. (n = 3 biological replicates, (*padj < 0.05, **padj < 0.0021, ***padj < 0.0002, ****padj < 0.0001, non-significant padj > 0.05 is not marked). Exact adjusted p values: (K) WT vs Exosc1-KO: 2.0 × 10⁻⁴, 7.0 × 10⁻⁴, 7.9 × 10⁻³, 2.2 × 10⁻²; (L) WT vs Exosc1-KO: 3.38 × 10⁻7, 4.42 × 10⁻13, 8.73 × 10⁻6, 3.73 × 10⁻7; WT vs Exosc1-KO + mCherry-V5: 1.14 × 10⁻7, 5.8 × 10⁻14, 6.05 × 10⁻7, 9.57 × 10⁻8; WT vs Exosc1-KO + Exosc1-V5: 4.34 × 10⁻². (M, N) Total RNA from wild-type, Exosc1-KO (M) and rescue (N) experiments was resolved on the agarose gel, followed by northern blot analysis. (O,P) Heatmap of northern blot quantifications for wild-type, Exosc1-KO (O) and rescue (P) experiments. Values were normalized to 7SK RNA, and the mean is presented relative to wild-type (n = 3 biological replicates). Statistical significance of the difference between a given sample and wild-type was determined with an unpaired t-test (for O) or two-way ANOVA (for P) and Holm–Šídák multiple comparison correction (n = 3 biological replicates. Black dots indicate instances with padj < 0.05.CC BY · PubMed Central
Figure EV5 Proteomics characterization of clonal Exosc1-KO mESCs, related to Fig. 4. (A) Volcano plots displaying whole proteome changes for Exosc1-KO. The log2 fold change (x axis) is plotted against the −log10 of Benjamini–Hochberg adjusted limma-moderated two-sided t-test p-value (y axis; padj). Dashed lines indicate the thresholds of padj < 0.05 and log2FC <−1 or >1 (n = 3 biological replicates). (B) Relative protein abundance of RNA exosome subunits in Exosc1-KO determined by shotgun and PRM mass-spectrometry. Values are shown relative to wild-type sample. Statistical significance of the difference between Exosc1-KO and wild-type was determined with an unpaired t-test and Holm–Šídák multiple comparison correction (n = 3 biological replicates). Black dots indicate instances where padj < 0.05. No signal for Exosc1 peptides was measured in Exosc1-KO samples and is depicted as n.d. (not determined). (C, D) Western blot analysis of wild-type, Exosc1-KO (C) and rescue cells (D) with the indicated antibody. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody and Actin represents a loading control. Asterisk (*) refers to the corresponding gel.
Figure EV5 Proteomics characterization of clonal Exosc1-KO mESCs, related to Fig. 4. (A) Volcano plots displaying whole proteome changes for Exosc1-KO. The log2 fold change (x axis) is plotted against the −log10 of Benjamini–Hochberg adjusted limma-moderated two-sided t-test p-value (y axis; padj). Dashed lines indicate the thresholds of padj < 0.05 and log2FC <−1 or >1 (n = 3 biological replicates). (B) Relative protein abundance of RNA exosome subunits in Exosc1-KO determined by shotgun and PRM mass-spectrometry. Values are shown relative to wild-type sample. Statistical significance of the difference between Exosc1-KO and wild-type was determined with an unpaired t-test and Holm–Šídák multiple comparison correction (n = 3 biological replicates). Black dots indicate instances where padj < 0.05. No signal for Exosc1 peptides was measured in Exosc1-KO samples and is depicted as n.d. (not determined). (C, D) Western blot analysis of wild-type, Exosc1-KO (C) and rescue cells (D) with the indicated antibody. Dilution series (10, 25, 50, and 100%) were used to estimate the sensitivity of the antibody and Actin represents a loading control. Asterisk (*) refers to the corresponding gel.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 46 Not checked · 137 Own results and interpretations

110 more claims

Create a free account to see all 183 claims and to verify the 72 references still open.

See all claims — free account
  • It may state two separate claims as one. 37
  • Probably not a substantial claim. 35

Create a free account to see these claims.

Citations

Cites

Show all 104 references

Cited by

Still being checked.

Metadata

Authors
Navalayeu, T., Beer, N., Bebjaková, M., Kalis, R. W., Hohmann, U., Stejskal, K., Krššáková, G., Fasching, N., Herzog, V. A., Popitsch, N., Roitinger, E., Plaschka, C., Zuber, J., & Ameres, S. L.
Affiliations
  • Institute of Molecular Biotechnology (AT)
  • University of Vienna (AT)
  • Research Institute of Molecular Pathology (AT)
Corresponding author
Ameres, Stefan L
Venue
The EMBO Journal
Published
2026-06-25
Volume
45
Issue
15
Pages
5423-5456
ISSN
  • 0261-4189 (ISSN-L)
  • 1460-2075
OpenAlex
W7165845145
Cited by
0
References
103
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • The EMBO Journal (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Vienna Science and Technology Fund (LS23-053)
  • EC | European Research Council (CoG-866166)
  • Austrian Science Fund (10.55776/F80, 10.55776/DOC177)
  • Boehringer Ingelheim Fonds (PhD Fellowship)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
RNA exosome, protein complex formation, Exo70, EXO1, proteostasis, ubiquitin-proteasome degradation, quality control, mouse embryonic stem cells, CRISPR/Cas9 mutagenesis, functional resilience
MeSH terms
Mouse Embryonic Stem Cells, Animals, RNA, RNA-Binding Proteins, Proteasome Endopeptidase Complex, Mice, Exosomes, Exosome Multienzyme Ribonuclease Complex, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cellular assembly and functional resilience of the mammalian RNA exosome. https://app.cochat.ai/papers/10.1038/s44318-026-00824-x
The paper
Navalayeu, T., Beer, N., Bebjaková, M., Kalis, R. W., Hohmann, U., Stejskal, K., Krššáková, G., Fasching, N., Herzog, V. A., Popitsch, N., Roitinger, E., Plaschka, C., Zuber, J., & Ameres, S. L. (2026). Cellular assembly and functional resilience of the mammalian RNA exosome. The EMBO Journal. https://doi.org/10.1038/s44318-026-00824-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.